Er Therapeutics Total Asset vs. Total Debt
| PNGM Stock | USD 0.0001 0.00 0.00% |
Er Therapeutics Total Assets |
|
For Er Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Er Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Er Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Er Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Er Therapeutics over time as well as its relative position and ranking within its peers.
PNGM |
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Er Therapeutics Total Debt vs. Total Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Er Therapeutics's current stock value. Our valuation model uses many indicators to compare Er Therapeutics value to that of its competitors to determine the firm's financial worth. Er Therapeutics is regarded second in total asset category among its peers. It also is regarded second in total debt category among its peers making up about 0.11 of Total Debt per Total Asset. The ratio of Total Asset to Total Debt for Er Therapeutics is roughly 8.74 . At this time, Er Therapeutics' Total Assets are very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Er Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.PNGM Total Debt vs. Total Asset
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Er Therapeutics |
| = | 423.6 K |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Er Therapeutics |
| = | 48.49 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
PNGM Total Debt vs Competition
Er Therapeutics is regarded second in total debt category among its peers. Total debt of Materials industry is at this time estimated at about 42.69 Billion. Er Therapeutics adds roughly 48,489 in total debt claiming only tiny portion of all equities under Materials industry.
Er Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Er Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Er Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Er Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Er Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -280.2 K | -294.2 K | |
| Net Loss | -384.3 K | -403.5 K | |
| Income Before Tax | -384.3 K | -403.5 K | |
| Total Other Income Expense Net | -104.1 K | -98.9 K | |
| Net Loss | -384.3 K | -403.5 K | |
| Net Loss | -384.3 K | -403.5 K | |
| Change To Netincome | 123.6 K | 129.8 K |
PNGM Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Er Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Er Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Er Therapeutics' important profitability drivers and their relationship over time.
Use Er Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Er Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Er Therapeutics will appreciate offsetting losses from the drop in the long position's value.Er Therapeutics Pair Trading
Er Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Er Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Er Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Er Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Er Therapeutics to buy it.
The correlation of Er Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Er Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Er Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Er Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Er Therapeutics position
In addition to having Er Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Pharmaceutical Products Thematic Idea Now
Pharmaceutical Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Pharmaceutical Products theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Pharmaceutical Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
To fully project Er Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Er Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Er Therapeutics' income statement, its balance sheet, and the statement of cash flows.